Unknown

Dataset Information

0

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.


ABSTRACT: BACKGROUND:Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT)?+?immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC). METHODS:The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modality was classified as stereotactic radiotherapy (SRT) to intra- and/or extracranial sites or non-SRT external beam RT (EBRT). OS was analyzed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS:In total, 44,498 patients were included (13% immunotherapy, 46.8% EBRT, and 4.7% SRT). On multivariate analysis, immunotherapy (hazard ratio [HR]:0.81, 95% confidence interval [CI]:0.78-0.83) and SRT (HR:0.78, 95%CI:0.70-0.78) independently associated with improved OS; however, the interaction term for SRT?+?immunotherapy was insignificant (p?=?0.89). For immunotherapy patients, the median OS for no RT, EBRT, and SRT was 14.5, 10.9, and 18.2?months, respectively (p?< 0.0001), and EBRT (HR:1.37, 95%CI:1.29-1.46) and SRT (HR:0.78, 95%CI:0.66-0.93) associated with OS on multivariate analysis. In the SRT subset, median OS for immunotherapy and chemotherapy was 18.2 and 14.3?months, respectively (p?=?0.004), with immunotherapy (HR:0.82, 95%CI:0.69-0.98) associating with OS on multivariate analysis. Furthermore, for patients receiving SRT, biologically effective dose (BED)?>?60?Gy was independently associated with improved OS (HR:0.79, 95%CI:0.70-0.90, p?< 0.0001) on multivariate analysis with a significant interaction between BED and systemic treatment (p?=?0.008). CONCLUSIONS:Treatment with SRT associated with improved OS for patients with metastatic NSCLC irrespective of systemic treatment. The high survival for patients receiving SRT?+?immunotherapy strongly argues for evaluation in randomized trials.

SUBMITTER: Foster CC 

PROVIDER: S-EPMC6348608 | biostudies-other | 2019 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.

Foster Corey C CC   Sher David J DJ   Rusthoven Chad G CG   Verma Vivek V   Spiotto Michael T MT   Weichselbaum Ralph R RR   Koshy Matthew M  

Radiation oncology (London, England) 20190128 1


<h4>Background</h4>Preclinical studies suggest enhanced anti-tumor activity with combined radioimmunotherapy. We hypothesized that radiation (RT) + immunotherapy would associate with improved overall survival (OS) compared to immunotherapy or chemotherapy alone for patients with newly diagnosed metastatic non-small-cell lung cancer (NSCLC).<h4>Methods</h4>The National Cancer Database was queried for patients with stage IV NSCLC receiving chemotherapy or immunotherapy from 2013 to 2014. RT modali  ...[more]

Similar Datasets

| S-EPMC10318269 | biostudies-literature
| S-EPMC5372697 | biostudies-literature
| S-EPMC7988369 | biostudies-literature
| S-EPMC7269798 | biostudies-literature
| S-EPMC7145732 | biostudies-literature
| S-EPMC5514258 | biostudies-literature
| S-EPMC8257645 | biostudies-literature
| S-EPMC5548189 | biostudies-literature
| S-EPMC7425589 | biostudies-literature
| S-EPMC10189015 | biostudies-literature